GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Total Liabilities

Prenetics Global (Prenetics Global) Total Liabilities : $44.01 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Total Liabilities?

Prenetics Global's Total Liabilities for the quarter that ended in Dec. 2023 was $44.01 Mil.

Prenetics Global's quarterly Total Liabilities declined from Jun. 2023 ($60.62 Mil) to Sep. 2023 ($47.63 Mil) and declined from Sep. 2023 ($47.63 Mil) to Dec. 2023 ($44.01 Mil).

Prenetics Global's annual Total Liabilities declined from Dec. 2021 ($549.40 Mil) to Dec. 2022 ($68.67 Mil) and declined from Dec. 2022 ($68.67 Mil) to Dec. 2023 ($44.01 Mil).


Prenetics Global Total Liabilities Historical Data

The historical data trend for Prenetics Global's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Total Liabilities Chart

Prenetics Global Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
- 47.88 549.40 68.67 44.01

Prenetics Global Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.67 57.51 60.62 47.63 44.01

Prenetics Global Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Prenetics Global's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.484+(0.867+1.047
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+2.615+0)
=44.01

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=254.171-210.157
=44.01

Prenetics Global's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.484+(0.867+1.047
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+2.615+0)
=44.01

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=254.171-210.157
=44.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prenetics Global Total Liabilities Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global (Prenetics Global) Business Description

Traded in Other Exchanges
N/A
Address
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.